Determinants of RASistance to anti-epidermal growth factor receptor agents

被引：63
作者：
Baselga, Jose [1 ,2 ]
Rosen, Neal [3 ]
机构：
[1] Vall Dhebron Univ Hosp, Barcelona, Spain
[2] Vall Dhebron Inst Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 10期
关键词：
D O I：
10.1200/JCO.2007.15.3700
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1582 / 1584
页数：3
相关论文
共 22 条
  • [1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, Rafael G.
    Wolf, Michael
    Peeters, Marc
    Van Cutsem, Eric
    Siena, Salvatore
    Freeman, Daniel J.
    Juan, Todd
    Sikorski, Robert
    Suggs, Sid
    Radinsky, Robert
    Patterson, Scott D.
    Chang, David D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
  • [2] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
    Benvenuti, Silvia
    Sartore-Bianchi, Andrea
    Di Nicolantonio, Federica
    Zanon, Carlo
    Moroni, Mauro
    Veronese, Silvio
    Siena, Salvatore
    Bardelli, Alberto
    [J]. CANCER RESEARCH, 2007, 67 (06) : 2643 - 2648
  • [3] Options available - from start to finish - for obtaining expression data by microarray
    Bowtell, DDL
    [J]. NATURE GENETICS, 1999, 21 (Suppl 1) : 25 - 32
  • [4] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) : 337 - 345
  • [5] De Roock W, 2007, ANN ONCOL
  • [6] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
    Di Fiore, F.
    Blanchard, F.
    Charbonnier, F.
    Le Pessot, F.
    Lamy, A.
    Galais, M. P.
    Bastit, L.
    Killian, A.
    Sesboue, R.
    Tuech, J. J.
    Queuniet, A. M.
    Paillot, B.
    Sabourin, J. C.
    Michot, F.
    Michel, P.
    Frebourg, T.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (08) : 1166 - 1169
  • [7] Targeting ras signalling pathways in cancer therapy
    Downward, J
    [J]. NATURE REVIEWS CANCER, 2003, 3 (01) : 11 - 22
  • [8] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    Eberhard, DA
    Johnson, BE
    Amler, LC
    Goddard, AD
    Heldens, SL
    Herbst, RS
    Ince, WL
    Jänne, PA
    Januario, T
    Johnson, DH
    Klein, P
    Miller, VA
    Ostland, MA
    Ramies, DA
    Sebisanovic, D
    Stinson, JA
    Zhang, YR
    Seshagiri, S
    Hillan, KJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5900 - 5909
  • [9] COSMIC 2005
    Forbes, S
    Clements, J
    Dawson, E
    Bamford, S
    Webb, T
    Dogan, A
    Flanagan, A
    Teague, J
    Wooster, R
    Futreal, PA
    Stratton, MR
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (02) : 318 - 322
  • [10] A metalloprotease-disintegrin, MDC9/meltrin-γ/ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor
    Izumi, Y
    Hirata, M
    Hasuwa, H
    Iwamoto, R
    Umata, T
    Miyado, K
    Tamai, Y
    Kurisaki, T
    Sehara-Fujisawa, A
    Ohno, S
    Mekada, E
    [J]. EMBO JOURNAL, 1998, 17 (24) : 7260 - 7272
123